Wednesday, October 22, 2014 Last update: 7:03 AM - Covering Large & Obscure Tech Companies Since 1996

New Report: Thymosin ?4 Prevents Heart Rupture & Improves Cardiac Function after Heart Attack in Mice

Companies mentioned in this article: RegeneRx Biopharmaceuticals, Inc.

ROCKVILLE, Md. -- (BUSINESS WIRE) -- RegeneRx Biopharmaceuticals, Inc. (OTC: RGRX) (“the Company” or “RegeneRx”) today announced that a new paper entitled, Thymosin β4 Prevents Cardiac Rupture and Improves Cardiac Function in Mice with Myocardial Infarction, was published in the journal, Heart Circulation Physiology, on July 11, 2014. “The present study shows for the first time that 1) Tβ4 is able to reduce incidence of cardiac rupture post-MI [myocardial infarction or heart attack] and markedly improved cardiac function at 5 weeks after MI, and that 2) the cardiac protective effects of Tβ4 after MI were associated with a significant reduction of excessive inflammatory response and cardiomyocyte apoptosis as well as with an enhancement of angiogenesis. From a clinical point of view, Tβ4 could potentially be a therapeutic candidate for patients with acute MI,” according to the study’s authors.

Animals were treated with Tβ4 daily at a relatively low dose for 7 days using a minipump implant. Treatment with Tβ4 ameliorated left ventricular dilation, improved cardiac function, and not only decreased the mortality rate due to cardiac rupture but also significantly improved cardiac function after MI.

The study received funding from the Henry Ford Health System and the National Institutes of Health. RegeneRx Biopharmaceuticals Inc. provided the Tβ4 under a Material Transfer Agreement.

About RegeneRx Biopharmaceuticals, Inc. (

RegeneRx is focused on the development of a novel therapeutic peptide, Thymosin β4, for tissue and organ protection, repair and regeneration. RegeneRx currently has three drug candidates in clinical development for ophthalmic, cardiac and dermal indications, three strategic licensing agreements in China, Pan Asia (Korea, Japan, and Australia, among others) and the EU, and has an extensive worldwide patent portfolio covering its products. Recently, RGN-259, the Company’s ophthalmic drug candidate has been designated as an orphan drug for the treatment of neurotrophic keratopathy, which is the primary focus of RegeneRx’s clinical development efforts in the U.S. For additional information about RegeneRx please visit

Forward-Looking Statements

Any statements in this press release that are not historical facts are forward-looking statements made under the provisions of the Private Securities Litigation Reform Act of 1995. Any forward-looking statements involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. There can be no assurance that any data or results described by the authors of the publication will be the subject of, or reproducible in, human clinical trials. Please view these and other risks described in the Company’s filings with the Securities and Exchange Commission (“SEC”), including those identified in the “Risk Factors” section of the annual report on Form 10-K for the year ended December 31, 2013, and subsequent quarterly reports filed on Form 10-Q, as well as other filings it makes with the SEC. Any forward-looking statements in this press release represent the Company’s views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. The Company specifically disclaims any obligation to update this information, as a result of future events or otherwise, except as required by applicable law.

Copyright © Business Wire 2014

For RegeneRx:
Lori Smith, 301-208-9191